Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Sep 03, 2022 11:14am
290 Views
Post# 34939996

RE:RE:RE:RE:RE:Scientists harness light therapy to target and kill cancer c

RE:RE:RE:RE:RE:Scientists harness light therapy to target and kill cancer c

It appears they are also still at the preclinical stages in reference to GBM (no humans tested).  But I also noted in the article that the European scientists were also very concerned about how to overcome the technical challenges of reaching deep-seated or less accessible solid tumors (like GBM) with near-infrared light.  The scientists were "excited to see how this research will develop".  Well, it looks like TLT may already have the advantage & answer to this technical challenge with its patented "x-ray activated" PDCs for destroying cancer.  

Perhaps our in-house patent expert, Pandora, could elaborate on this...does the patent extend to all forms of radiotherapy?

<< Previous
Bullboard Posts
Next >>